Stony Brook University Cancer Center presents a day of learning at the new built Stony Brook MART. "Immune and Emerging Therapy for Patients with Gastrointestinal Cancer" is a course designed to provide participants with the most up-to-date information in gastrointestinal diagnostics, therapeutics, chemotherapy, targeted therapy, immunotherapy, novel radiation and surgical techniques. This course emphasizes the evidence-based approach to personalized care for GI cancers.
To Register for this event, please use the following link:
Dates and Times
Start: 10/20/2018 7:00 AM
End: 10/20/2018 3:00 PM
- Review the clinical evidence for immunotherapy in patients with hepatobiliary, gastric and colorectal cancer and identify important biomarkers for immune check point inhibition.
- Identify new targeted and systemic therapies in the treatment of gastric, colorectal, hepatobiliary, pancreatic cancer and neuroendocrine cancer with the focus on newly approved FDA agents.
- Engage physicians and healthcare workers to best clinical practice in the treatment of gastric, hepatobiliary, colorectal, pancreatic, carcinoid and other GI cancers.
- Integrate clinical data and guideline recommendations on the optimal use of VEGF tyrosine kinase inhibitors in treatment protocols for patients with refractory colorectal cancer and hepatobiliary cancers.
- Review innovative diagnostic, medical, and surgical techniques that is emerging for gastrointestinal cancer.
Stony Brook University Medical Center
101 Nicolls Road
MART Building, Lauterbur Drive
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.